Medtech startup Sleepiz has successfully completed a second closing of its Series A financing round. The company was able to raise an additional CHF 1.8 million. The fresh capital will primarily be used to launch the sleep apnea monitor in foreign markets.
With its eponymous device, Sleepiz has developed a convenient and cost-effective way to screen for sleep and diagnose sleep disorders such as sleep apnea. The startup, which has over 50 employees, has just announced the second closing of its Series A round, bringing the total volume for Series A to CHF 6.2 million.
"We will use the newly raised capital to further roll out our monitor for the diagnosis of sleep disorders," says Max Sieghold, co-founder of Sleepiz. "The launch in Germany is planned for the coming weeks. Other countries will follow." The main investors in the first closing included Verve Ventures, ZKB, a U.S. health insurance company and the four judges of "Höhle der Löwen Schweiz.
ETH Zurich spinoff Sleepiz has developed the first contactless monitor, approved as a medical device in Europe, to measure breathing rate and diagnose sleep disorders such as sleep apnea. People suffering from poor sleep need only request it online or have it prescribed by their doctor and place it next to their bed for three nights.
The device monitors nighttime breathing with 99 percent accuracy - without any wiring. The data generated is simultaneously transmitted to a cloud platform and analyzed in the form of reports and trend analyses so that it can be discussed with an expert.
(Press release / SK)
Please login or sign up to comment.
Commenting guidelines